These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 31217827)
61. Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. O'Donoghue LE; Ptitsyn AA; Kamstock DA; Siebert J; Thomas RS; Duval DL BMC Cancer; 2010 Sep; 10():506. PubMed ID: 20860831 [TBL] [Abstract][Full Text] [Related]
62. ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma. Cam M; Gardner HL; Roberts RD; Fenger JM; Guttridge DC; London CA; Cam H Oncotarget; 2016 Jul; 7(30):48533-48546. PubMed ID: 27391430 [TBL] [Abstract][Full Text] [Related]
63. Williams IP; Crescioli S; Sow HS; Bax HJ; Hobbs C; Ilieva KM; French E; Pellizzari G; Cox V; Josephs DH; Spicer JF; Karagiannis SN; Mele S MAbs; 2020; 12(1):1685349. PubMed ID: 31769737 [TBL] [Abstract][Full Text] [Related]
64. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563 [TBL] [Abstract][Full Text] [Related]
65. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. Yu X; Qu L; Bigner DD; Chandramohan V Protein Eng Des Sel; 2017 Sep; 30(9):639-647. PubMed ID: 28981720 [TBL] [Abstract][Full Text] [Related]
66. PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology. Maniscalco L; Iussich S; Morello E; Martano M; Biolatti B; Riondato F; Della Salda L; Romanucci M; Malatesta D; Bongiovanni L; Tirrito F; Gattino F; Buracco P; De Maria R Vet J; 2013 Jan; 195(1):41-7. PubMed ID: 22704137 [TBL] [Abstract][Full Text] [Related]
67. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. Inkol JM; Poon AC; Mutsaers AJ Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984 [TBL] [Abstract][Full Text] [Related]
69. Clinical significance and in vitro cellular regulation of hypoxia mimicry on HIF-1α and downstream genes in canine appendicular osteosarcoma. Gola C; Iussich S; Noury S; Martano M; Gattino F; Morello E; Martignani E; Maniscalco L; Accornero P; Buracco P; Aresu L; De Maria R Vet J; 2020 Oct; 264():105538. PubMed ID: 33012439 [TBL] [Abstract][Full Text] [Related]
70. Cytotoxic action of Brazilian propolis in vitro on canine osteosarcoma cells. Cinegaglia NC; Bersano PR; Búfalo MC; Sforcin JM Phytother Res; 2013 Sep; 27(9):1277-81. PubMed ID: 23074147 [TBL] [Abstract][Full Text] [Related]
71. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Flint AF; U'Ren L; Legare ME; Withrow SJ; Dernell W; Hanneman WH Vet Pathol; 2004 May; 41(3):291-6. PubMed ID: 15133183 [TBL] [Abstract][Full Text] [Related]
72. Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts. Milovancev M; Hilgart-Martiszus I; McNamara MJ; Goodall CP; Seguin B; Bracha S; Wickramasekara SI BMC Vet Res; 2013 Jun; 9():116. PubMed ID: 23758893 [TBL] [Abstract][Full Text] [Related]
73. PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma - Walewska M; Małek A; Taciak B; Wojtalewicz A; Wilk S; Wojtkowska A; Zabielska-Koczywąs K; Lechowski R J Vet Res; 2023 Jun; 67(2):297-305. PubMed ID: 37786430 [TBL] [Abstract][Full Text] [Related]
74. Investigating TrkA expression in canine appendicular osteosarcoma. Fan TM; Barger AM; Sprandel IT; Fredrickson RL J Vet Intern Med; 2008; 22(5):1181-8. PubMed ID: 18638015 [TBL] [Abstract][Full Text] [Related]
75. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Simpson S; Dunning MD; de Brot S; Grau-Roma L; Mongan NP; Rutland CS Acta Vet Scand; 2017 Oct; 59(1):71. PubMed ID: 29065898 [TBL] [Abstract][Full Text] [Related]
76. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924 [TBL] [Abstract][Full Text] [Related]
77. Interleukin-11 receptor alpha is expressed on canine osteosarcoma. Sottnik JL; Thamm DH Vet Comp Oncol; 2010 Jun; 8(2):96-102. PubMed ID: 20579322 [TBL] [Abstract][Full Text] [Related]
78. Impact of telomerase status on canine osteosarcoma patients. Kow K; Thamm DH; Terry J; Grunerud K; Bailey SM; Withrow SJ; Lana SE J Vet Intern Med; 2008; 22(6):1366-72. PubMed ID: 18761602 [TBL] [Abstract][Full Text] [Related]
79. Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF. Uranowska K; Kalic T; Valtsanidis V; Kitzwögerer M; Breiteneder H; Hafner C Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649790 [TBL] [Abstract][Full Text] [Related]